

Name of the organisation: MCRN the Netherlands

Year: 2016

Transparency

If applicable, please provide a link to or a copy of the latest financial report (optional)¹: **MCRN The Netherlands is a Non-funded expertise network**

Information on activities undertaken by the organisation are regularly published on the organisation website	Yes		No
Financial reports are available on the organisation website			No

Please provide the names of all donors (both public and private) and their individual financial contribution in terms of percentage of the overall budget:

Industry² related income to the coordinating centre unrestricted or designated to support the generic, infrastructure of the network

Name of company/ funder	Amount of income ³	Percentage of overall budget (optional)
None	0	0
Subtotal:		

Industry related income to the network or its sites to conduct drug trials or to prepare for drug trials

Name of company/ funder (including trial sponsor or intermediary company, or CRO etc...)	Amount of income ⁴ (optional)	Percentage of overall budget (optional)
None	0	0
Subtotal:		0

¹ The report is intended to inform participants (industry, other networks etc.) in specific meetings rather than be evaluated by EMA / EnprEMA. The role of EnprEMA here is to promote standards for reporting rather than to enforce those standards.

² Industry is defined as commercial manufacturers of healthcare products and services, including distributors and wholesalers, etc.

³ This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

⁴ This should reflect the overall funding received from industry, including, e.g. projects, conferences, etc.

Non-industry related income to the coordinating centre unrestricted or designated to support the generic, infrastructure of the network		
Source of funding ⁵	Amount of income (optional)	Percentage of overall budget (optional)
None	0	0
Subtotal:		
TOTAL:		

Non-industry related income to the network or its sites to conduct drug trials or to prepare for drug trials		
Source of funding ⁶	Amount of income (optional)	Percentage of overall budget (optional)
NOne	0	0
Subtotal:		
TOTAL:		

The information above is to be published on the network's webpages, by Q1 of the following year (e.g. 2015 information to be included by March 2016).

To ensure transparency all Enpr-EMA members are encouraged to publish as much information as possible regarding funding sources; therefore all Enpr-EMA members are requested to provide links to requested documents where applicable, including the latest official annual financial statement.

⁵ E.g. membership fees, donations.

⁶ E.g. membership fees, donations.